Filing Flows › Phathom Pharmaceuticals (PHAT) › R&D spending
Phathom Pharmaceuticals (PHAT) R&D spending by quarter
Phathom Pharmaceuticals' R&D spending was $8.7M in Q3 2026 (third quarter 2026), +12% from Q2 2026. Over the last 7 quarters it ranged from $7.0M (Q3 2025) to $9.2M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $8.7M | +12% | +24% |
| Q2 2026 | $7.8M | +0.5% | -14% |
| Q1 2026 | $7.8M | +4% | -15% |
| Q4 2025 | $7.5M | +7% | — |
| Q3 2025 | $7.0M | -23% | — |
| Q2 2025 | $9.1M | -1% | — |
| Q1 2025 | $9.2M | — | — |
Q3 2026 at a glance
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Phathom Pharmaceuticals' R&D spending?
Phathom Pharmaceuticals' R&D spending was $8.7M in Q3 2026 (third quarter 2026), +12% from Q2 2026.
How has Phathom Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $7.0M (Q3 2025) to $9.2M (Q1 2025).
Q3 2026 results → · How Phathom Pharmaceuticals makes money →